Pam3CSK4 enhanced beta cell loss and diabetogenesis: The roles of IFN-gamma and IL-17

Clinical Immunology

Volumn 149, Issue 1, 2013, Pages 86-96

  Al Shamsi, Mariam ^a   Shahin, Allen ^a   Iwakura, Yoichiro ^b   Lukic, Miodrag L ^c   Mensah Brown, Eric P K ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Apoptosis; Autoimmunity; Proinflammatory cytokines; Subdiabetogenic dose

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; PAM 3CSK 4; STREPTOZOCIN; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BETA CELL LOSS; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL LOSS; CONTROLLED STUDY; DENDRITIC CELL; DIABETES MELLITUS; DIABETOGENESIS; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; LYMPH NODE CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

APOPTOSIS; AUTOIMMUNITY; PROINFLAMMATORY CYTOKINES; SUBDIABETOGENIC DOSE;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DIABETES MELLITUS, EXPERIMENTAL; INSULIN-SECRETING CELLS; INTERFERON-GAMMA; INTERLEUKIN-17; LIPOPEPTIDES; LYMPH NODES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880956826     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.06.001     Document Type: Article

References (46)

1. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., Takeda K., Akira S. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999, 11:443-451.
2. Fujimoto C., Yu C.R., Shi G., Vistica B.P., Wawrousek E.F., Klinman D.M., Chan C.C., Egwuagu C.E., Gery I. Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J. Immunol. 2006, 177:6896-6903.
3. Ber A.A. Endogenous ligands of Toll-like receptors, Implications for regulating inflammatory and immune responses. Trends Immunol. 2002, 23:509-512.
4. Akira S. Mammalian Toll-like receptors. Curr. Opin. Immunol. 2003, 15:5-11.
5. Toubi E., Shoenfeld Y. Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity 2004, 37:183-186.
6. Patel M., Xu D., Kewin P., Choo-Kang B., McSharry C., Thomson N.C., Liew F.Y. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J. Immunol. 2005, 1742:7558-7563.
7. + T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 2010, 32:692-702.
8. Allprantis A.O., Yang R.B., Weiss D.D., Godowski P., Zychlinsky A. The apoptotic signaling pathway activator by toll-like receptor 2. EMBO J. 2000, 19:3325-3336.
9. Kim H.S., Han M.S., Chung K.W., Kim S., Ki M.J., Jang E., Lee H.A., Youn J., Akira S., Lee M.S. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 2007, 27:321-333.
10. + regulatory T cells. PNAS 2006, 103:7048-7053.
11. Friesen N.T.E., Buchau A.S., Schott-Ohly P., Lgssiar A., Gleichmann H. Generation of hydrogen peroxide and failure of antioxidative responses in pancreatic islets of male C57BL/6 mice are associated with diabetes induced by multiple low doses of streptozotocin. Diabetologia 2004, 47:676-685.
12. Chol S.E., Noh H.L., Kim H.M., Yoon J.W., Kang Y. Streptozotocin upregulates GAD67 expression in MIN6N8a mouse beta cells. J. Autoimmun. 2002, 19:1-8.
13. Mensah-Brown E.P.K., Shahin A., Al-Shamisi M., Wei X., Lukic M.L. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur. J. Immunol. 2006, 36:216-223.
14. Lukic M.L., Mensah-Brown E., Wei X., Shahin A., Liew F.Y. Lack of the mediators of innate immunity attenuates the development of autoimmune diabetes in mice. J. Autoimmun. 2003, 21:239-246.
15. Lamhamedi-Cherradi S.E., Zheng S., Tisch R.M., Chen Y.H. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 2003, 52:2274-2278.
16. Nicoletti F., Di Marco R., Papaccio G., Conget I., Gomis R., Bernadini R., Sims J.E., Shoenfeld Y., Bendtzen K. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin, prevention of hyperglycemia and insulitis by a recombinant IL-18-binding protein: Fc construct. Eur. J. Immunol. 2003, 33:2278-2286.
17. Pechhold K., Patterson N.B., Blum C., Fleischacker C.L., Boehm B.O., Harlan D.M. Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28 dependent. J. Immunol. 2001, 166:2531-2539.
18. Nakae S., Komiyama Y., Nambu A., Sudo K., Iwase M., Homma I., Sekikawa K., Asano M., Iwakura Y. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17:375-387.
19. Lacy P.E., Kostianovsky M. Method of isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967, 16:35-39.
20. Lernmark A. The preparation of, and studies on, free cell suspensions from mouse pancreatic islets. Diabetologia 1974, 10:431-438.
21. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., Mc-Clanahan T., Kastelein R.A., Sedgwick J.D., Cua D.J. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 2003, 198:1951-1957.
22. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S.A., Gorman D., Kastelein R.A., Sedgwick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
23. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
24. Kolb H., Burkart V., Appels B., Hanenberg H., Kantwerk-Funke G., Kiesel U., Funda J., Schraermeyer U., Kolb-Bachofen V. Essential contribution of macrophages to islet cell destruction in vivo and in vitro. J. Autoimmun. 1990, (Suppl. 1):117-120.
25. Lukic M., Stosic-Grujicic S., Shahin A. Effector mechanisms in low-dose streptozotocin-induced diabetes. Dev. Immunol. 1998, 6:119-128.
26. Eldor R., Yeffer A., Baum K., Doviner V., Amar D., Ben-Neriah Y., Christofori G., Peled A., Carel J.C., Boitard C., Klein T., Serup P., Eizirik D.L., Melloul D. Conditional and specific NF-{kappa}B blockade protects pancreatic beta cells from diabetogenic agents. PNAS 2006, 103:5072-5077.
27. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
28. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
29. Homo-Delarche F., Drexhage H.A. Immune cells, pancreas development, regeneration and type 1diabetes. Trends Immunol. 2004, 25:222-229.
30. Rosmalen J.G., Leenen P.J., Katz J.D., Voerman J.S., Drexhage H.A. Dendritic cells in the autoimmune insulitis in NOD mouse models of diabetes. Adv. Exp. Med. Biol. 1997, 417:291-294.
31. Haase C., Skak K., Michelsen B.K., Markholst H. Local activation of dendritic cells leads to insulitis and development of insulin-dependent diabetes in transgenic mice expression of? CD154 on the pancreatic β-cells. Diabetes 2004, 53:2588-2595.
32. +T cells, expanded with dendritic cells presenting a single autoantigen peptide, suppress autoimmune diabetes. J. Exp. Med. 2004, 199:1467-1477.
33. Pasare C., Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004, 21:733-741.
34. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005, 6:345-352.
35. Rudensky A.Y., Gavin M., Zheng Y. FOXP3 and NFAT: partners in tolerance. Cell 2006, 126:253-256.
36. + T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
37. + regulatory cell activation and function by dendritic cells. Int. Immunol. 2004, 16:1769-1780.
38. + T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Front. Biosci. 2006, 11:1360-1370.
39. Hill N., Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr. Opin. Immunol. 2002, 14:791-797.
40. Gysemans C.A., Pavlovic D., Bouillon R., Eizirik D.L., Mathieu C. Dual role of interferon-gamma signaling pathway in sensitivity of pancreatic beta cells to immune destruction. Diabetologia 2001, 44:567-574.
41. Rasschaert J., Ladrière L., Irbain M., Dogusan Z., Katabua B., Sata S., Akira S., Gysemans C., Mathieu C., Eizirik D.L. Toll-like receptor 3 and STAT-1 contribute for dsRNA+INF-γ-induced apoptosis in primary pancreatic β-cells. J. Biol. Chem. 2005, 280:33984-33991.
42. Gysemans C.A., Ladriere L., Callewaert H., Rasschaert J., Flamez D., Levy D.E., Matthys P., Eizirik D.L., Mathieu C. Disruption of the γ-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of β cells. Diabetes 2005, 54:2396-2403.
43. Thoma-Uszynski S., Kiertscher S.M., Ochoa M.T., Bouis D.A., Norgard M.V., Miyake K., Godowski P.J., Roth M.D., Modlin R.L. Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12 but not IL-10. J. Immunol. 2000, 165:3804.
44. Xu D., Komai-Koma M., Liew F.Y. Expression and function of toll-like receptor on T cells. Cell. Immunol. 2005, 233:85-89.
45. O'Connor R.A., Prendergast C.T., Sabatos C.A., Lau C.W., Leech M.D., Wraith D.C., Anderton S.M. Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 2008, 181:3750-3754.
46. Mensah-Brown E.P.K., Al Rabesi Z., Shahin A., Al Shamsi M., Arsenijevic N., Hsu D.K., Liu F.T., Lukic M.L. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin. Immunol. 2009, 130:83-88.